Although the efficacy of CTLA-4 inhibitors alone in NSCLC patients is limited, combination therapy with PD-1/PD-L1 inhibitors may lead to improved treatment outcomes. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.